Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$5.30 - $25.29
Next Earnings Date
May 01 2025
Next Earnings Date
May 01 2025
Last Price
Market Cap | $1.78B |
EV | $1.81B |
Shares Outstanding | 88.77M |
Beta | 0.84 |
Analyst Rating | BUY |
Analyst Target Price | $33.67 |
P/E 2025E | - |
P/Revenue 2025E | 4.62x |
Revenue | 0.80% |
EPS | -22.20% |
Operating Cash Flow | -152.30% |
Free Cash Flow | -58.40% |
Revenue | 48.00% |
EPS | - |
Operating Cash Flow | 51.60% |
Free Cash Flow | - |
Gross Margin 2025E | 94.00% |
Net Profit Margin 2025E | -33.05% |
ROE 2025E | -166.60% |
ROCE 2024 | -246.75% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Travere Therapeutics, Inc.
TVTX
Sector
Healthcare
Industry
Biotechnology
CEO
Dube, Eric
Employees
385
Website
www.travere.comIPO Date
2012-11-08
Headquarters
3611 Valley Centre Drive, Suite 300, San Diego, California, 92130, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved